#4-85E. Unlocking New Horizons in SLE Therapy: The PHOENYCS GO Trial of Dapirolizumab Pegol (Lancet, 2026)

Can we effectively control disease activity in systemic lupus erythematosus (SLE) while concurrently minimizing the long-term organ damage caused by glucocorticoids? In this episode, we explore the PHOENYCS GO trial, a phase 3, randomized, double-blind study evaluating dapirolizumab pegol, a novel CD40 ligand inhibitor, in patients with moderate-to-severe active SLE. By adding this biological agent to standard-of-care medication, researchers observed a significantly higher BICLA response rate at week 48 compared to the placebo group. The study’s most critical finding highlights the drug's unique Fc domain-deficient structure, which safely achieves broad immune modulation, effectively reducing both debilitating fatigue and the necessary glucocorticoid dosage without the thromboembolic risks associated with earlier CD40L-targeting therapies. However, when critically appraising this paper, listeners should consider the limitation of a reduced sample size due to the COVID-19 pandemic, which may constrain the robustness of long-term safety and rare adverse event evaluations. For clinicians, this paper is highly relevant as it introduces a promising, upstream therapeutic option that not only addresses complex immunopathology but also facilitates crucial steroid-sparing strategies, potentially transforming the daily management of patients refractory to conventional treatments.

Citation: Megan E B Clowse, et al. Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 407(2291-2304), 2026. DOI: 10.1016/S0140-6736(26)00691-4

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.